GENENTECH, INC for GENENTECH INC
What was lobbied
10 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
H.R. 2163/S. 464 - Safe Step Act S.1773 - Prescription Drug Pricing Dashboard Act H.R. 5376 - Build Back Better Act H.R. 3684- Infrastructure Investment and Jobs Act H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act S.2076/H.R. 3932 PASTEUR Act S. 3799- PREVENT Pandemics Act H.R.4521 - COMPETES Act of 2022 S.1260 - United States Innovation and Competition Act of 2021 H.R.6963 - Accelerated Approval Integrity Act of 2022 H.R.6996 - Accelerating Access for Patients Act of 2022 H.R. 2565 / S.2952 the FDA Modernization Act H.R. 6972 - Give Kids a Chance Act H.R. 1730 - STAT Act H.R. 7032 - Increasing Transparency in Generic Drug Applications Act H.R. 5030/S. 2706 - DIVERSE Trials Act H.R. 6584 - DEPICT Act -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation -Patient access to Part B medicines during the COVID-19 public health emergency -Issues related to health equity, diversity, and inclusion in clinical trials -Issues related to advanced development and procurement of medical countermeasures (MCMs) -Issues related to patient assistance and access -Issues relating to privacy and securing the data of and personal information of consumers -Issues relating to medical research data -Issues relating to screening and diagnostics -Issues related to public health preparedness and response
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAVID COOLING | — |
| CALEB GRAFF New | — |
| CATHERINE LYTTON PHILLIPS | — |
| JILL SHOTZBERGER | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Copyright/Patent/Trademark CPT
S. 2891 - Restoring the America Invents Act -Intellectual property and process patent issues -Patent litigation reforms -PTAB and IPR processes -Section 101 Reform -Domestic and international compulsory licensing issues -March-in Rights
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
Health Issues HCR
H.R. 2163/S. 464 - Safe Step Act S.1773 - Prescription Drug Pricing Dashboard Act H.R. 5376 - Build Back Better Act H.R. 3684- Infrastructure Investment and Jobs Act H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act S.2076/H.R. 3932 PASTEUR Act S. 3799- PREVENT Pandemics Act H.R.4521 - COMPETES Act of 2022 S.1260 - United States Innovation and Competition Act of 2021 H.R.6963 - Accelerated Approval Integrity Act of 2022 H.R.6996 - Accelerating Access for Patients Act of 2022 H.R. 2565 / S.2952 the FDA Modernization Act H.R. 6972 - Give Kids a Chance Act H.R. 1730 - STAT Act H.R. 7032 - Increasing Transparency in Generic Drug Applications Act H.R. 5030/S. 2706 - DIVERSE Trials Act H.R. 6584 - DEPICT Act -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation -Patient access to Part B medicines during the COVID-19 public health emergency -Issues related to health equity, diversity, and inclusion in clinical trials -Issues related to advanced development and procurement of medical countermeasures (MCMs) -Issues related to patient assistance and access -Issues relating to privacy and securing the data of and personal information of consumers -Issues relating to medical research data -Issues relating to screening and diagnostics -Issues related to public health preparedness and response
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAVID COOLING | — |
| CALEB GRAFF New | — |
| DAN NEVES | — |
| CATHERINE LYTTON PHILLIPS | — |
| JILL SHOTZBERGER | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Medicare/Medicaid MMM
H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125 - the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -Issues related to CMMI
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| CALEB GRAFF New | — |
| CATHERINE LYTTON PHILLIPS | — |
| JILL SHOTZBERGER | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Taxation/Internal Revenue Code TAX
H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act H.R. 5376 - Build Back Better Act H.R.4521 - COMPETES Act of 2022 S.1260 - United States Innovation and Competition Act of 2021 -Issues related to R&D tax deductions and expense amortization -Issues related to international taxation, including foreign-derived intangible income and interest deductions -Issues related to supply chain incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| CATHERINE LYTTON PHILLIPS | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Trade (domestic/foreign) TRD
H.R. 3788, the Protecting American Innovation Act H.R. 3811, the Trade Related Intellectual Property Protection Act H.R. 7185, the Federal Contracting for Peace and Security Act -Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver -Issues related to compulsory licensing of foriegn patents -Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
Medical/Disease Research/Clinical Labs MED
H.R. 2471 Consolidated Appropriations Act, FY2022 S.2076/H.R. 3932 PASTEUR Act H.R.7667 - Food and Drug Amendments of 2022 S.4348 - FDASLA Act of 2022 H.R.6963 - Accelerated Approval Integrity Act of 2022 H.R.6996 - Accelerating Access for Patients Act of 2022 H.R. 2565 / S.2952 the FDA Modernization Act H.R. 6972 - Give Kids a Chance Act H.R. 1730 - STAT Act H.R. 7032 - Increasing Transparency in Generic Drug Applications Act H.R. 5030/S. 2706 - DIVERSE Trials Act H.R. 6584 - DEPICT Act H.R.3085 - ENACT Act of 2021 -Issues related to public health protection including influenza development and preparedness -Issues related to antimicrobial and antiviral research and product development -Issues related to novel coronavirus and COVID-19 research and product development -Issues related to drug development including PDUFA and Cures 2.0
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAVID COOLING | — |
| DAN NEVES | — |
| CATHERINE LYTTON PHILLIPS | — |
Pharmacy PHA
H.R. 2163/S. 464 - Safe Step Act H.R. 5376 - Build Back Better Act H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act -Drug pricing issues -Prescription Drug User Fee Act reauthorization -Issues related to prescription drug value -Issues related to the 340B Drug Discount Program
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAVID COOLING | — |
| CATHERINE LYTTON PHILLIPS | — |
| JILL SHOTZBERGER | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Manufacturing MAN
S.3401 - Safe Drug Act H.R. 7121, Protecting our Pharmaceutical Supply Chain from China Act of 2022 S.3509 - Creating Efficiency in Foreign Facility Inspections Act -Issues related to pharmaceutical supply chains -Issues related to reporting on location of origin of pharmaceutical products -Issues related to drug shortages -Issues related to pharmaceutical manufacturing
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN NEVES | — |
| JILL SHOTZBERGER | — |
| THOMAS L. STOLL | — |
Immigration IMM
-Issues relating to limits and restrictions on the immigration of high skilled workers -Issues relating to the immigration of medical researchers
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.